Neutropenia, Hypertension Are Independent Biomarkers of Sunitinib Efficacy

Share this content:
On-treatment neutropenia and hypertension are independent biomarkers of efficacy in patients with metastatic renal cell carcinoma.
On-treatment neutropenia and hypertension are independent biomarkers of efficacy in patients with metastatic renal cell carcinoma.

On-treatment neutropenia and hypertension are independent biomarkers of efficacy in patients with metastatic renal cell carcinoma (mRCC), a recent study published online ahead of print in the British Journal of Cancer has shown.1

For the study, researchers led by Frede Donskov, MD, DMSc, of the Aarhus University Hospital Department of Oncology in Denmark, sought to evaluate whether mRCC prognostic models may be improved by including sunitinib-induced toxicities.

Researchers analyzed data from 770 patients with mRCC treated with the tyrosine kinase inhibitor sunitinib. They looked at baseline prognostic factors, treatment-induced toxicities, such as hypertension, neutropenia, thrombocytopenia, hand-foot syndrome, and asthenia/fatigue, and progression-free and overall survival.

Results showed that on-treatment neutropenia and hypertension were significantly independently associated with longer progression-free survival (P = .0276 and P < .0001, respectively) and overall survival (P =.0014 and P < .0001, respectively.

By landmark analysis at 12 weeks, neutropenia was significantly associated with longer progression-free and overall survival (P = .013 and P =.0122, respectively, while hypertension or hand-foot syndrome were associated with longer overall survival (P =.0036 and P =.0218, respectively).

RELATED: Analysis Suggests Partial Nephrectomy Is New Gold Standard for Small Renal Masses

The findings suggest that including neutropenia and hypertension as independent biomarkers of sunitinib efficacy may add prognostic accuracy to the International Metastatic Renal Cell carcinoma Database Consortium (IMDC) criteria.

In a clinical trial that included 375 patients with treatment-naïve advanced RCC who received sunitinib, 34% experienced hypertension and 77% experienced neutropenia.

Reference

  1. Donskov F, Michaelson MD, Puzanov I, et al. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients [published online ahead of print October 22, 2015]. Br J Cancer. doi: 10.1038/bjc.2015.368.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters